{"nctId":"NCT02105285","briefTitle":"Efficacy and Safety Study of OPC-1085EL Ophthalmic Solution in Subjects With Glaucoma or Ocular Hypertension","startDateStruct":{"date":"2014-04"},"conditions":["Glaucoma","Ocular Hypertension"],"count":193,"armGroups":[{"label":"OPC-1085EL ophthalmic solution","type":"EXPERIMENTAL","interventionNames":["Drug: OPC-1085EL ophthalmic solution"]},{"label":"Carteolol long-acting ophthalmic solution","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Carteolol long-acting ophthalmic solution"]}],"interventions":[{"name":"OPC-1085EL ophthalmic solution","otherNames":[]},{"name":"Carteolol long-acting ophthalmic solution","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Subjects with diagnosis of bilateral primary open-angle glaucoma or ocular hypertension\n\nExclusion Criteria:\n\n* Subjects with ocular conditions as defined by the protocol","healthyVolunteers":false,"sex":"ALL","minimumAge":"20 Years","maximumAge":"80 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Decrease From Baseline in Intraocular Pressure at Week 8 Predose","description":"Comparison of each group in change from baseline in intraocular pressure. Arm of \"a treatment group coming together with latanoprost / carteolol\" is a reference group． As for \"Primary Outcome\" and \"Secondary Outcome\" analysis , the OPC-1085EL group was compared only to the carteolol group, not to the latanoprost/carteolol concomitant group.","paramType":"MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3.5","spread":null},{"groupId":"OG001","value":"1.6","spread":null}]}]}]},{"type":"SECONDARY","title":"Intraocular Pressure at Week 8 Predose","description":"Comparison of each group in intraocular pressure at Week 8 Predose. Arm of \"a treatment group coming together with latanoprost / carteolol\" is a reference group． As for \"Primary Outcome\" and \"Secondary Outcome\" analysis , the OPC-1085EL group was compared only to the carteolol group, not to the latanoprost/carteolol concomitant group.\n\nThe number of subjects showed in the Participant Flow comes from all the subjects administered IMP. For efficacy analysis, on the other hand, several subjects were excluded from the analysis according to the statistical analysis plan. For example, subjects without IOP after administration were excluded. In addition, IOP measurement at 8 hours was not mandatory. That is why there are differences between the number in the Participant Flow and Outcome.","paramType":"MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"16.3","spread":"0.2"},{"groupId":"OG001","value":"18.2","spread":"0.2"}]}]}]},{"type":"SECONDARY","title":"Intraocular Pressure at Week 8 at 2 Hours After IMP Administration","description":"Comparison of each group in intraocular pressure at Week 8 at 2 hours after IMP administration.\n\nArm of \"a treatment group coming together with latanoprost / carteolol\" is a reference group． As for \"Primary Outcome\" and \"Secondary Outcome\" analysis , the OPC-1085EL group was compared only to the carteolol group, not to the latanoprost/carteolol concomitant group.\n\nThe number of subjects showed in the Participant Flow comes from all the subjects administered IMP. For efficacy analysis, on the other hand, several subjects were excluded from the analysis according to the statistical analysis plan. For example, subjects without IOP after administration were excluded. In addition, IOP measurement at 8 hours was not mandatory. That is why there are differences between the number in the Participant Flow and Outcome.","paramType":"MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"15.7","spread":"0.2"},{"groupId":"OG001","value":"17.8","spread":"0.2"}]}]}]},{"type":"SECONDARY","title":"Intraocular Pressure at Week 8 at 8 Hours After IMP Administration","description":"Comparison of each group in intraocular pressure at Week 8 at 8 hours after IMP administration.\n\nArm of \"a treatment group coming together with latanoprost / carteolol\" is a reference group． As for \"Primary Outcome\" and \"Secondary Outcome\" analysis , the OPC-1085EL group was compared only to the carteolol group, not to the latanoprost/carteolol concomitant group.\n\nThe number of subjects showed in the Participant Flow comes from all the subjects administered IMP. For efficacy analysis, on the other hand, several subjects were excluded from the analysis according to the statistical analysis plan. For example, subjects without IOP after administration were excluded. In addition, IOP measurement at 8 hours was not mandatory. That is why there are differences between the number in the Participant Flow and Outcome.","paramType":"MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"15.2","spread":"0.2"},{"groupId":"OG001","value":"17.9","spread":"0.3"}]}]}]},{"type":"SECONDARY","title":"Decrease From Baseline in Intraocular Pressure at Week 8 at 2 Hours After IMP Administration","description":"Comparison of each group in change from baseline in intraocular pressure at Week 8 at 2 hours after IMP administration.\n\nArm of \"a treatment group coming together with latanoprost / carteolol\" is a reference group． As for \"Primary Outcome\" and \"Secondary Outcome\" analysis , the OPC-1085EL group was compared only to the carteolol group, not to the latanoprost/carteolol concomitant group.\n\nThe number of subjects showed in the Participant Flow comes from all the subjects administered IMP. For efficacy analysis, on the other hand, several subjects were excluded from the analysis according to the statistical analysis plan. For example, subjects without IOP after administration were excluded. In addition, IOP measurement at 8 hours was not mandatory. That is why there are differences between the number in the Participant Flow and Outcome.","paramType":"MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.9","spread":null},{"groupId":"OG001","value":"0.8","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Intraocular Pressure at Week 8 at 8 Hours After IMP Administration","description":"Comparison of each group in change from baseline in intraocular pressure at Week 8 at 8 hours after IMP administration.\n\nArm of \"a treatment group coming together with latanoprost / carteolol\" is a reference group． As for \"Primary Outcome\" and \"Secondary Outcome\" analysis , the OPC-1085EL group was compared only to the carteolol group, not to the latanoprost/carteolol concomitant group.\n\nThe number of subjects showed in the Participant Flow comes from all the subjects administered IMP. For efficacy analysis, on the other hand, several subjects were excluded from the analysis according to the statistical analysis plan. For example, subjects without IOP after administration were excluded. In addition, IOP measurement at 8 hours was not mandatory. That is why there are differences between the number in the Participant Flow and Outcome.","paramType":"MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3.0","spread":null},{"groupId":"OG001","value":"0.3","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":78},"commonTop":["Conjunctival hyperaemia","Nasopharyngitis","Eye irritation","Eye pain","Ocular hyperaemia"]}}}